FDA Places CT1812, Potential Disease-Modifying Alzheimer’s Treatment, on Fast Track

FDA Places CT1812, Potential Disease-Modifying Alzheimer’s Treatment, on Fast Track
The U.S. Food and Drug Administration (FDA) has placed CT1812 on fast track as a potential treatment of patients with Alzheimer’s disease (AD), the investigative therapy’s developer,  Cognition Therapeutics, has announced. CT1812 is a first-in-class, orally administered small molecule designed to inhibit the binding of amyloid beta oligomers to nerve cell receptors in the brain. Amyloid beta oligomers

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

4 comments

  1. Dante J Marciani says:

    Interesting research that strengthens the crucial role of amyloid-beta in Alzheimer’s disease (AD). It also provides support to the notion that natural protective antibodies against amyloid oligomers can be an effective way to prevent AD. Considering the complexities of AD, it is possible to speculate that combinations of different methods, e.g. immune prevention plus CT1812, due to potential synergism would be more effective that either therapy alone. Maybe it is time to discard past misleading dubious findings and to accept new concepts and approaches like those that led to the development of this promising compound.

  2. Joe Finn says:

    Dante, looks promising..
    I know of one company also presenting at CTAD that might be a great adjunct therapy, Anavex’s A2-73..A Potent Sigma One/Muscarinic Agonist.
    the more solutions the better!

  3. Jim says:

    A more promising drug, Anavex 2-73 is showing a curative effect on Alz. CT1812 continues down the same track of trying to cure the disease by fixing the backend. If you really want to report on something that is shifting the way people think take a look at their drug.

Leave a Comment

Your email address will not be published. Required fields are marked *